|Bid||4.900 x 1200|
|Ask||5.090 x 900|
|Day's Range||4.900 - 5.250|
|52 Week Range||4.280 - 9.600|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
IRIDEX Corporation (IRIX) today announced the appointment of Dr. Robert Grove to the Company’s Board of Directors effective October 15, 2018. Concurrently, Ann Rhoads will step down from the Board of Directors to focus attention on her new responsibility as Chief Financial Officer of Forty Seven Inc. “Bob is a perfect fit for our Board of Directors and will be an excellent addition,” said William M. Moore, Chairman and Chief Executive Officer.
Anyone researching IRIDEX Corporation (NASDAQ:IRIX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...
The offering is expected to close on September 18, 2018, subject to customary closing conditions. Gross proceeds to the Company from the offering are expected to be approximately $10,000,000 before deducting the underwriting discount and other offering expenses payable by the Company and excluding any exercise of the underwriters' option.
IRIDEX Corporation (IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. IRIDEX also expects to grant the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by IRIDEX. IRIDEX intends to use the net proceeds from the offering for working capital and other general corporate purposes.
The TruFocus LIO Premiere is a light combination and reflection viewing system used with IRIDEX retina laser systems and is worn on the physician’s head. The product combines a laser treatment beam from an IRIDEX laser source with the illumination beam of a binocular indirect ophthalmoscope into a mixed optical beam used by a physician with a handheld ophthalmic examination lens to enter a patient’s pupil and to view and treat a patient’s retina. “We are pleased to again be offering our full portfolio of laser delivery devices to doctors in the U.S.,” said William M. Moore, President and Chief Executive Officer.
IRIDEX Corporation (Nasdaq: IRIX), a leading provider of innovative laser systems in ophthalmology, is pleased to announce that the Company’s Cyclo G6 Glaucoma Laser System is used in 35 of the 39 “Best Hospitals for Ophthalmology” as ranked in a recent report by U.S. News and World Report. The Cyclo G6 system is the first in its class designed specifically to treat patients diagnosed with a range of glaucoma disease states. It features the Company’s proprietary MicroPulse® technology, in which a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period allowing the tissue to cool between laser pulses.
The Mountain View, California-based company said it had a loss of 28 cents per share. The medical laser company posted revenue of $10.3 million in the period. Iridex expects full-year revenue in the range ...
MOUNTAIN VIEW, Calif., Aug. 02, 2018-- IRIDEX Corporation today reported financial results for the second quarter and six months ended June 30, 2018.. Cyclo G6™ product revenue increased approximately ...
MOUNTAIN VIEW, Calif., July 19, 2018-- IRIDEX Corporation today announced the Company will release financial results for the second quarter 2018 after the close of trading on Thursday, August 2, 2018. ...
IRIDEX Corporation (NASDAQ:IRIX), a medical equipment company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a smallRead More...
On a per-share basis, the Mountain View, California-based company said it had a loss of 31 cents. The medical laser company posted revenue of $9.5 million in the period. Iridex shares have declined 27 ...
NEW YORK , March 20, 2018 /PRNewswire/ -- BioScrip, Inc. (BIOS) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with BioScrip's disclosure that it ...
On a per-share basis, the Mountain View, California-based company said it had a loss of 44 cents. The medical laser company posted revenue of $10.2 million in the period. For the year, the company reported ...
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / IRIDEX Corporation (NASDAQ: IRIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 5:00 PM Eastern Time. ...